Innovating For Patients
Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.
About Us
Targeted and Innovative CNS Therapies
Trevena’s novel pipeline includes five product candidates that are being developed for areas of critical need in CNS and other disorders. All of the company’s assets are new chemical entities with unique mechanisms of action that target well-known receptors. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
| Program | Molecular Target | Therapeutic Target | Current Phase | PC | PH1 | PH2 | PH3 | NDA | Approved |
|---|---|---|---|---|---|---|---|---|---|
| OLINVYK™ (oliceridine) injection | Mu receptor | Acute pain | Approved | PC complete | PH1 complete | PH2 complete | PH3 complete | NDA complete | Approved in progress |
| TRV027 | AT1 receptor | ARDS / abnormal clotting (COVID-19) | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV250 | Delta receptor | Acute migraine | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV734 | Mu receptor | Opioid use disorder | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV045 | S1P receptor | CNS disorders | PC | PC in progress | PH1 not started | PH2 not started | PH3 not started | NDA not started | Approved not started |
The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.
